Latest insights

The Big Shrink – How to navigate High Yield markets?

Charudatta Shende, Nicolas Jullien, Fixed Income, Research Paper
High yield markets are shrinking. Do you know that they have contracted by 25% over the past two years? The ICE BofA BB-B Global High Yield Index has lost $654 million in value. In the meanwhile, investor demand for credit and high yield has rebounded at the end of last year.
  • Asset Allocation, Macro, Equities, Fixed Income, Nicolas Forest, Nadège Dufossé, Emile Gagna

    Update on Middle East Tensions

    On April 13, Iran decided to strike Israel with 300 drones and missiles following an attack on its diplomatic compound in Syria. Regional escalation and oil price are at risk. This tail risk cannot be ignored. We are closely monitoring the unfolding situation.
  • ESG, SRI, David Czupryna, Circular Economy

    Beyond Fossil Fuels: Why Green Investments Are Still the Future

    After a challenging period for green investing, marked by rising interest rates, supply chain issues, and overcapacity, companies committed to building a sustainable world could remain an attractive long-term option for investors seeking both financial returns and positive impact.
6 results found
  • Rudi Van Den Eynde
Show me
  • Topic
  • Theme
  • Publication
  • Author
Find it fast
Show me
  • Topic
  • Theme
  • Publication
from
  • Author
6 results found
  • Rudi Van Den Eynde
Malgorzata Kluba, Rudi Van Den Eynde, Oncology, Equities

World Cancer Day 2023

And we would rather not have to go through this – which would mean we won the battle and cancer is curable.
Outlook 2023, Rudi Van Den Eynde

Building a New World: Thematic Investments

In the United States Antonín Dvořák composed the New World Symphony in 1893 and Neil Armstrong took it on a cassette to the moon. Rudi Van den Eynde takes it global, presenting us a New World of long-term trends.
Q&A, Health Care, Rudi Van Den Eynde

Biotech investing: is there a doctor in the house?

Rudi Van Den Eynde, Head of Thematic Global Equity at Candriam, answers investors’ questions about a sector where depth of specialist knowledge is a prerequisite to consistent stock selection success.
Oncology, Q&A, Rudi Van Den Eynde, Equities

Investing in oncology: forewarned is forearmed

Rudi Van Den Eynde, Head of Thematic Global Equity at Candriam, explains to investors the approach he used to create and develop an investment strategy in the oncology sector.

Find it fast

Get information faster with a single click

Get insights straight to your inbox